ToxSci Advance Access published online on April 14, 2004
Toxicological Sciences, doi:10.1093/toxsci/kfh144
Toxicological Sciences © Society of Toxicology 2004; all rights reserved
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 GlaxoSmithKline Inc. Safety Assessment, Investigative Toxicology and Pathology, Research Triangle Park, NC 27709
* To whom correspondence should be addressed. E-mail: heidi.m.colton{at}gsk.com.
Peroxisome proliferation in the liver is a well-documented response that occurs in some species upon treatment with hypolipidemic drugs, such as fibrates. Typically, liver peroxisome proliferation has been estimated by direct counting via electron microscopy, as well as by gene expression, enzyme activity and immunolabeling. We have developed a novel method for the immunofluorescent labeling of peroxisomes using an antibody to the 70-kDa peroxisomal membrane protein (PMP70) coupled with fluorescent nanocrystals (Quantum DotsTM). This method is applicable to standard formalin-fixed paraffin-embedded tissues. Using this technique, a dose-dependent increase in PMP70 labeling was evident in formalin-fixed liver sections from fenofibrate-treated rats. In formalin-fixed liver sections from cynomolgus monkeys given ciprofibrate, quantitative image analysis showed a statistically significant increase in PMP70 labeling compared to control; the increase in hepatic PMP70 protein levels was corroborated by immunoblotting using total liver protein. An increase in hepatic peroxisome number in ciprofibrate-treated monkeys was confirmed by electron microscopy. An advantage of the Quantum DotTM/PMP70 method is that a single common protocol can be used to label peroxisomes from several different species, and many of the common problems that arise with immunolabeling are eliminated, such as fading and low signal strength.
© 2004 Toxicological Sciences © Society of Toxicology 2004; all rights reserved.
Systems Evaluation
Visualization and Quantitation of Peroxisomes Using Fluorescent Nanocrystals: Treatment of Rats and Monkeys with Fibrates and Detection in the Liver
2 Hepatotech Inc., Pittsboro, NC 27312
Abstract 
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  B. Faiola, J. G. Falls, R. A. Peterson, N. R. Bordelon, T. A. Brodie, C. A. Cummings, E. H. Romach, and R. T. Miller PPAR alpha, more than PPAR delta, Mediates the Hepatic and Skeletal Muscle Alterations Induced by the PPAR Agonist GW0742 Toxicol. Sci., October 1, 2008; 105(2): 384 - 394. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. F. Waring, Y. Yang, C. H. Healan-Greenberg, A. L. Adler, R. Dickinson, T. McNally, X. Wang, M. Weitzberg, X. Xu, A. Lisowski, et al. Gene Expression Analysis in Rats Treated with Experimental Acetyl-Coenzyme A Carboxylase Inhibitors Suggests Interactions with the Peroxisome Proliferator-Activated Receptor {alpha} Pathway J. Pharmacol. Exp. Ther., February 1, 2008; 324(2): 507 - 516. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. C. Noland, T. L. Woodlief, B. R. Whitfield, S. M. Manning, J. R. Evans, R. W. Dudek, R. M. Lust, and R. N. Cortright Peroxisomal-mitochondrial oxidation in a rodent model of obesity-associated insulin resistance Am J Physiol Endocrinol Metab, October 1, 2007; 293(4): E986 - E1001. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. A. Styles, J. L. Falany, S. Barnes, and C. N. Falany Quantification and regulation of the subcellular distribution of bile acid coenzyme A:amino acid N-acyltransferase activity in rat liver J. Lipid Res., June 1, 2007; 48(6): 1305 - 1315. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Kwanyuen, S. M. Witherspoon, D. R. Creech, H. M. Colton, J. G. Falls, and N. F. Cariello Flow Cytometric Assessment of Peroxisome Proliferation from Frozen Liver of Fibrate-Treated Monkeys International Journal of Toxicology, January 1, 2006; 25(1): 41 - 47. [Abstract] [Full Text] [PDF]
|
|